Arcutis Biotherapeutics Announces Closing of Underwriters’ Over-Allotment Option in Connection with Public Offering of Common Stock

Feb 16, 2021

WESTLAKE VILLAGE, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, announced that it has completed the sale of an additional 825,000 shares of common stock, pursuant to the exercise in full of the overallotment option granted to the underwriters in connection with the Company’s recently completed underwritten public offering of 5,500,000 shares of common stock, at the public offering price of $35.00 per share, less underwriting discounts and commissions. After giving effect to the sale of these additional shares, a total of 6,325,000 shares of common stock were sold in the offering, for aggregate gross proceeds of approximately $221.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Arcutis.

Morgan Stanley, Cowen, and Guggenheim Securities acted as bookrunning managers for the offering. Truist Securities and Cantor acted as lead managers for the offering.

The public offering was made pursuant to an automatic shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission (the "SEC") on February 1, 2021 and automatically became effective upon filing. A final prospectus supplement and accompanying prospectus relating to and describing the final terms of the offering were filed with the SEC and are available on the SEC's website located at or may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at; Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (833) 297-2926, or by email at; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison, 8th Floor, New York, New York 10017, by telephone at (212) 518-9658, or by email at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Arcutis - Bioscience, applied to the skin.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.

Forward Looking Statements
This press release contains "forward-looking" statements. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause Arcutis’ actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause Arcutis’ actual results to differ include risks and uncertainties associated with the effect of changing economic conditions, risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and Arcutis’ ability to defend its intellectual property. Arcutis’ business could be affected by a number of other factors, including the risk factors discussed in the preliminary prospectus supplement relating to the offering and the documents incorporated by reference therein, which include Arcutis’ Quarterly Reports on Form 10-Q and Annual Report on Form 10-K. The forward-looking statements contained in this press release speak only as of the date hereof and Arcutis cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Arcutis disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Heather Rowe Armstrong
Vice President, Investor Relations & Corporate Communications
805-418-5006, Ext. 740

Print Page
RSS Feeds
Email Alerts